Peptide hormones

Glooko Announces Digital Health Collaboration with Eli Lilly's Connected Insulin Pen Solutions in Global Markets

Retrieved on: 
Thursday, May 6, 2021

The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.

Key Points: 
  • The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.
  • "Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes.
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.

MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021

Retrieved on: 
Wednesday, May 5, 2021

MannKind is currently commercializing Afrezza\xc2\xae (insulin human) Inhalation Powder, the Company\xe2\x80\x99s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

Key Points: 
  • MannKind is currently commercializing Afrezza\xc2\xae (insulin human) Inhalation Powder, the Company\xe2\x80\x99s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.
  • Afrezza is also available by prescription in Brazil where it is commercialized by the Company\xe2\x80\x99s partner Biomm SA.
  • MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.
  • The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com .\n"

Insulet to Present at BofA Securities 2021 Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 4, 2021

b'Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod\xc2\xae brand of products, today announced that management will present at the virtual BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 4:15 p.m. (Eastern Time).\nTo listen to the live audio webcast of the presentation, please visit http://investors.insulet.com .

Key Points: 
  • b'Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod\xc2\xae brand of products, today announced that management will present at the virtual BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 4:15 p.m. (Eastern Time).\nTo listen to the live audio webcast of the presentation, please visit http://investors.insulet.com .
  • The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods.
  • With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle.
  • Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment

Retrieved on: 
Wednesday, April 28, 2021

b'Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK).

Key Points: 
  • b'Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK).
  • \xe2\x80\x9cCARE-HK in HF will investigate the patterns of RAASi use, and barriers to treatment optimization, and examine whether adherence to guidelines is associated with improved real-world outcomes.
  • CARE-HK in HF will help the medical community to better understand the potential value of Veltassa\xc2\xae in treating hyperkalemia.
  • They will be receiving renin-angiotensin-aldosterone system inhibitors and either receiving, or be candidates for, mineralocorticoid receptor antagonist (MRA) treatment per a relevant treatment guideline.

Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar

Retrieved on: 
Tuesday, April 27, 2021

Miller and Cassorla will be available to answer questions following the formal presentations.

Key Points: 
  • Miller and Cassorla will be available to answer questions following the formal presentations.
  • As has been previously disclosed in adults, LUM-201 increased the pulsatile release of growth hormone for 24 hours in Predictive Enrichment Marker (PEM) Positive subjects (N=2).
  • In children, this rare disorder is called pediatric growth hormone deficiency (PGHD).
  • LUM-201 has received Orphan Drug Designation in both the US and EU.\xc2\xa0For more information, please visit www.lumos-pharma.com .\n'

China Recombinant Lispro Insulin Market Report 2021-2025 with Situation of Diabetes and Overview of the Antidiabetic drug Market in China

Retrieved on: 
Tuesday, April 27, 2021

Its preparation is recombinant insulin lispro injection, protamine zinc recombinant insulin lispro Mixed injection (25R) and protamine zinc recombinant insulin lispro mixed injection (50R) which can better control blood sugar and reduce the occurrence of hypoglycemia.\nThe original research drug of recombinant lispro insulin was developed by Eli Lilly.

Key Points: 
  • Its preparation is recombinant insulin lispro injection, protamine zinc recombinant insulin lispro Mixed injection (25R) and protamine zinc recombinant insulin lispro mixed injection (50R) which can better control blood sugar and reduce the occurrence of hypoglycemia.\nThe original research drug of recombinant lispro insulin was developed by Eli Lilly.
  • Eli Lilly\'s Recombinant Lispro Insulin Injection (trade name: Humalog), Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R) (trade name: Humalog Mix25), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) (trade name: Humalog Mix50), approved by the FDA for the treatment of diabetes from April 1996 to December 1999, were released in 2005, 2010, and 2008 respectively in China.\nIn the Chinese market, until the end of 2020, apart from Eli Lilly\'s original drug Humalog, there are only Recombinant Lispro Insulin Injection and Recombinant Insulin Glargine Injection from the local Chinese company Ganli Pharmaceutical Co., Ltd., which were launched in 2006 and 2014 respectively.\nRecombinant Lispro Insulin has been developing rapidly since it entered China, with annual sales value increasing from less than CNY 7 million in 2005 to CNY254 million in2020.\nThe only Recombinant Lispro Insulin manufacturers on the Chinese market are Lilly and Gan & Lee Pharmaceuticals.
  • Optimistic about China\'s Recombinant Lispro Insulin market, some other domestic pharmaceutical companies are stepping up the imitation of Recombinant Lispro Insulin.\nFor example, in Oct. 2018, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that the CFDA had approved the clinical trials of its Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R).
  • It is expected that in the next few years, more Recombinant Lispro Insulin products by domestic pharmaceutical companies will be launched.\nIt is expected that as the number of diabetic patients continues to increase, China\'s Recombinant Lispro Insulin market will still have some growth potential.\n2 Sales of Recombinant Lispro Insulin in China, 2016-2020\n2.3 Sales of Recombinant Lispro Insulin by Dosage Form in China, 2016-2020\n3 Analysis of Major Recombinant Lispro Insulin Manufacturers in China, 2016-2020\n4 Prices of Recombinant Lispro Insulin in China, 2020-2021\n5 Prospect of China\'s Recombinant Lispro Insulin Market, 2021-2025\n'

Fractyl Announces FDA Breakthrough Device Designation for Revita® DMR in Insulin-Treated Type 2 Diabetes

Retrieved on: 
Tuesday, April 27, 2021

b'Fractyl Laboratories Inc. ( Fractyl ), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Revita\xc2\xae DMR in patients with insulin-treated type 2 diabetes (T2D).

Key Points: 
  • b'Fractyl Laboratories Inc. ( Fractyl ), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Revita\xc2\xae DMR in patients with insulin-treated type 2 diabetes (T2D).
  • We know that treatment alternatives to current drug therapy are desperately needed to address the type 2 diabetes epidemic,\xe2\x80\x9d said Juan Carlos Lopez-Talavera, M.D., Ph.D., Chief Medical Officer of Fractyl.
  • Revita DMR has received FDA Breakthrough Device Designation and a European Union CE mark.
  • Fractyl\xe2\x80\x99s lead program is Revita DMR, an outpatient endoscopic procedural therapy designed to treat insulin resistance in type 2 diabetes.

Glytec Raises $21 Million To Set the Standard for Hospital Insulin Dosing and Glycemic Management

Retrieved on: 
Monday, April 26, 2021

The funding will fuel Glytec\xe2\x80\x99s mission of revolutionizing the role glycemic management plays in the hospital across every department.

Key Points: 
  • The funding will fuel Glytec\xe2\x80\x99s mission of revolutionizing the role glycemic management plays in the hospital across every department.
  • However, nearly 90% of the more than 6,000 hospitals across the United States still use one-size-fits-all, simplistic insulin dosing protocols.
  • Learn more at www.savitrcapital.com/ .\nGlytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care.
  • For more information, follow Glytec on Twitter ( @Glytec ) and LinkedIn , or visit www.GlytecSystems.com .\n'

China Recombinant Lispro Insulin Market Report 2021-2025 Featuring Lilly & Gan & Lee Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 21, 2021

Its preparation is recombinant insulin lispro injection, protamine zinc recombinant insulin lispro Mixed injection (25R) and protamine zinc recombinant insulin lispro mixed injection (50R) which can better control blood sugar and reduce the occurrence of hypoglycemia.\nThe original research drug of recombinant lispro insulin was developed by Eli Lilly.

Key Points: 
  • Its preparation is recombinant insulin lispro injection, protamine zinc recombinant insulin lispro Mixed injection (25R) and protamine zinc recombinant insulin lispro mixed injection (50R) which can better control blood sugar and reduce the occurrence of hypoglycemia.\nThe original research drug of recombinant lispro insulin was developed by Eli Lilly.
  • Eli Lilly\'s Recombinant Lispro Insulin Injection (trade name: Humalog), Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R) (trade name: Humalog Mix25), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) (trade name: Humalog Mix50), approved by the FDA for the treatment of diabetes from April 1996 to December 1999, were released in 2005, 2010, and 2008 respectively in China.\nIn the Chinese market, until the end of 2020, apart from Eli Lilly\'s original drug Humalog, there are only Recombinant Lispro Insulin Injection and Recombinant Insulin Glargine Injection from the local Chinese company Ganli Pharmaceutical Co., Ltd., which were launched in 2006 and 2014 respectively.\nRecombinant Lispro Insulin has been developing rapidly since it entered China, with annual sales value increasing from less than CNY 7 million in 2005 to CNY254 million in 2020.\nThe only Recombinant Lispro Insulin manufacturers on the Chinese market are Lilly and Gan & Lee Pharmaceuticals.
  • Optimistic about China\'s Recombinant Lispro Insulin market, some other domestic pharmaceutical companies are stepping up the imitation of Recombinant Lispro Insulin.\nFor example, in Oct. 2018, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that the CFDA had approved the clinical trials of its Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R).
  • It is expected that in the next few years, more Recombinant Lispro Insulin products by domestic pharmaceutical companies will be launched.\nIt is expected that as the number of diabetic patients continues to increase, China\'s Recombinant Lispro Insulin market will still have some growth potential.\n2 Sales of Recombinant Lispro Insulin in China, 2016-2020\n2.3 Sales of Recombinant Lispro Insulin by Dosage Form in China, 2016-2020\n3 Analysis of Major Recombinant Lispro Insulin Manufacturers in China, 2016-2020\n4 Prices of Recombinant Lispro Insulin in China, 2020-2021\n5 Prospect of China\'s Recombinant Lispro Insulin Market, 2021-2025\n'

Rapid Acting Insulin Market to Garner $8.92 Bn, Globally, by 2027 at 4.1% CAGR: Allied Market Research

Retrieved on: 
Thursday, April 22, 2021

b'PORTLAND, Ore., April 22, 2021 /PRNewswire/ -- Allied Market Research recently published a report, titled, " Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20202027".

Key Points: 
  • b'PORTLAND, Ore., April 22, 2021 /PRNewswire/ -- Allied Market Research recently published a report, titled, " Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 20202027".
  • As per the report, the global rapid acting insulin industry was accounted for $7.10 billion in 2019, and is estimated to reach $8.92 billion by 2027, growing at a CAGR of 4.1% from 2020 to 2027.\nRise in availability of continuous glucose monitoring, surge in investments in R&D for human recombinant insulin, and increase in government expenditure on healthcare drive the growth of the global rapid acting insulin market.
  • However, adverse effects associated with use of rapid acting insulin hinder the market growth.
  • However, the global rapid acting insulin market across Asia-Pacific is estimated to register the highest CAGR of 5.8% during the forecast period, owing to westernized lifestyle behaviors and the increased prevalence of obesity.\n'